Parabilis Medicines' chief medical officer to depart in September
Fawzi Benzaghou, M.D., will leave the company on September 30, 2026, under a mutual agreement disclosed in an 8-K filing.
Parabilis Medicines, Inc. disclosed in an 8-K filed with the SEC that its Chief Medical Officer, Fawzi Benzaghou, M.D., will leave the company. The company and Dr. Benzaghou reached a mutual agreement on August 28, 2026 that his last day with the company would be September 30, 2026.1
The filing states that Dr. Benzaghou will be entitled to severance under the terms of his existing employment agreement with the company.1 The filing does not specify the dollar amount or other details of that severance package.
The 8-K, filed under Item 5.02 covering officer departures and appointments, was signed on September 2, 2026 by Thomas Kotarakos, the company's Chief Financial Officer. Parabilis Medicines is based in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Stock Market under the ticker symbol PBLS.
The filing does not name a successor Chief Medical Officer or describe any transition arrangements beyond the departure date and severance provision.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.